Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS SECRETARY BOWEN NOMINATES JOSEPH STETLER FOR RxPRC

Executive Summary

HHS SECRETARY BOWEN NOMINATES JOSEPH STETLER FOR RxPRC membership. Currently of counsel with D.C. law firm Hyman Phelps & McNamara, the former PMA president was named as a candidate for one of 11 positions on the Prescription Drug Payment Review Commission (RxPRC). Under the Catastrophic Care Act, enacted July 1, the commission will be appointed by the Office of Technology Assessment to monitor the financial health of the newly authorized Medicare drug program. OTA hopes to select the commission by November ("The Pink Sheet" Sept. 5, p. 3). Other nominees include American Health Care Registry President Judith Willis, who was nominated by HHS Undersecretary Don Newman. Raymond Gosselin, currently executive editor of the pharmacy magazine Pharmacy Times, was nominated by William Hassan, Jr., the chairman of the Board of Trustees of the Massachusetts College of Pharmacy and Allied Health Sciences. Gosselin is former president of the pharmacy school. OTA has received slightly more than 140 nominations. The agency expects the final tally of names to be around 160.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel